This is a working overview of Synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-26 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
The first whole genome sequencing study to comprehensively catalog de novo structural variation at a much higher resolution than DNA microarray studies has shown that the mutation rate is approximately 20% and not elevated in autism compared to sibling controls. Structural variants in individuals with autism are much larger and four times more likely to disrupt genes, mirroring findings from CNV studies. CNV studies were closely followed by exome sequencing studies, which sequence the 1–2% of the genome that codes for proteins (the "exome"). These studies found that de novo gene inactivating mutations were observed in approximately 20% of individuals with autism, compared to 10% of unaffected siblings, suggesting the etiology of autism is driven by these mutations in around 10% of cases. There are predicted to be 350-450 genes that significantly increase susceptibility to autism when impacted by inactivating de novo mutations. A further 12% of cases are predicted to be caused by protein altering missense mutations that change an amino acid but do not inactivate a gene. Therefore, approximately 30% of individuals with autism have a spontaneous de novo large CNV that deletes or duplicates genes, or mutation that changes the amino acid code of an individual gene. A further 5–10% of cases have inherited structural variation at loci known to be associated with autism, and these known structural variants may arise de novo in the parents of affected children.
== Pathophysiology == PMD is an idiopathic, non-inflammatory condition. The thinning of the cornea may approach 20% of normal thickness. There may be an increase in the number of mucopolysaccharides in the corneal stroma. The Bowman's layer of the cornea may be absent, irregular, or have ruptured areas.
=== Fresno mold and ropiness === In the mid-20th century, a cottony mycelium-like growth began appearing in the bottles of some sweet fortified wines produced in California's Central Valley. Being fortified, these wines often had alcohol levels in excess of 20% which is usually a level that discourages growth of most spoilage organisms associated with winemaking. Nicknamed "Fresno mold" due to where it was first discovered, the culprit of this growth was determined to be L. fructivorans, a species which can be controlled by sanitation and maintaining adequate sulfur dioxide levels. Some Lactobacillus and Pediococcus species (particularly P. damnosus and P. pentosaceus) have the potential to synthesize polysaccharides that add an oily viscosity to the wine. In the case of Lactobacillus, some of these saccharides may be glucans that can be synthesized from glucose present in the wine as low as 50–100 mg/L (0.005 to 0.01% residual sugar) and afflict seemingly "dry" wines. While "ropiness" can occur in the barrel or tank, it is often observed in the wines several months after they are bottled. Wines with pH levels above 3.5 and low sulfur dioxide levels are at most risk for developing this fault. Called graisse (or "grease") by the French and les vins filant by Pasteur, this fault has been observed in apple wines and cider. It can also be potentially be caused by other spoilage microbes such as Streptococcus mucilaginous, Candida krusei, and Acetobacter rancens.
Like CMX-1152, the herbal mixture known as Protandim that supplanted it was marketed by Lifeline as an "anti-aging" supplement that increases the body's antioxidant defenses by upregulating superoxide dismutase, catalase, and glutathione peroxidase. According to the company, the product was initially sold through retail channels such as GNC; however, in 2009, after several consecutive years of multimillion-dollar losses, the company, which by then was doing business under the name LifeVantage, stopped marketing it through retailers and switched to multi-level marketing, selling it instead through a network of commissioned independent distributors. According to LifeVantage, the move from retail to multi-level marketing was prompted by the January 2008 hiring of David W. Brown, (formerly CEO and president of Metabolife) as the company's CEO and president. Beginning in 2005, Protandim was produced under a manufacturing agreement with The Chemins Company of Colorado Springs, Colorado. In July 2008, LifeVantage entered into a new manufacturing agreement with Cornerstone Research & Development to produce Protandim, and with Wasatch Product Development to produce a Protandim-based skin cream (TrueScience). In 2006, biochemist Joe M. McCord joined the LifeVantage board of directors as the company's director of science. McCord, who is listed by the U.S. Securities and Exchange Commission as a LifeVantage insider shareholder, served as a spokesperson for Protandim and was responsible for distributor training and product research.
Sources: en.wikipedia.org
== Importance in winemaking == Assimilable nitrogen is an essential nutrient needed by wine yeast in order to fully complete fermentation with a minimum amount of undesirable by-products (such as compounds like hydrogen sulfide that can create off odors) created. Over the course of a fermentation, yeast may use up to a 1000 mg/L of amino acids though often far less than amount is needed. Yeast can store amino acids in intracellular vacuoles and then later either use them directly, incorporating them into proteins, or break them down and use their carbon and nitrogen components separately. In the absence of nitrogen, yeast will begin to shut down and die off. Some strains will begin breaking down sulfur containing amino acids like cysteine and methionine releasing a sulfur atom that can combine with hydrogen to produce hydrogen sulfide (H2S) which can impart rotten egg odors to the wine. However, there is not a direct correlation between YAN levels and hydrogen sulfide production since H2S can be produced by yeast even in the presence of abundant nitrogen but with instead other vital nutrients (such as the vitamin pantothenic acid) lacking. There are even some strains of S. cerevisiae that produce H2S as a response to having too much available nitrogen (particularly too much glutamic acid and alanine). This is why a prophylactic approach of indiscriminately adding nitrogen supplementation to every fermentation may not have the desired results of preventing H2S.
The power law model is used to display the behavior of Newtonian and non-Newtonian fluids and measures shear stress as a function of strain rate. The relationship between shear stress, strain rate and the velocity gradient for the power law model are:
== Research == Thymosin α1 (TA1), a molecule with immune enhancing properties, was the first of the thymosins to enter clinical trials. It has been approved in China and more than 30 other countries, and has shown great promise in the treatment of severe sepsis, cancer, and a number of other diseases including the potential treatment of cystic fibrosis. Most recently, TA1 has been found to synergize with a check-point inhibitor and further extend the survival of Stage III/IV melanoma patients previously treated with TA1. Thymosin β4 (Tβ4), the second of the thymosins to reach the clinic, has been shown to accelerate wound healing and the remodeling of injured tissues. An injectable form of Tβ4 has been developed for internal indications such as myocardial infarction, stroke and brain trauma. Early Phase 2 trials have been completed in patients with pressure and venostasis ulcers. Two Phase 2/3 trials in patients with dry eye and neurotrophic keratopathy have been completed in the United States with promising results. A third Phase 3 trial in dry eye will begin in 2019. RegeneRx Biopharmaceuticals is developing an injectable form of Tβ4 for internal indications such as myocardial infarction, stroke, multiple sclerosis, brain trauma, and peripheral neuropathy. Dr. Goldstein's research has helped define the role of biological response modifiers in health and disease, and has led to the discovery of important new links between the immune system, the neuroendocrine system and the brain.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.